

277. Randi ML, Tison T, Luzzatto G. Haemolytic uraemic syndrome during treatment with ketorolac trometamol. *BMJ* 1993 Jan 16; 306: 186
278. Sitz KV, Engler RJM, Carpenter GB. Ketorolac tromethamine (Toradol) induced asthma: a case report. *Ann Allergy* 1992 Jan; 68: 115
279. Alamar R, Arrufat R, Castelló JV, et al. Ketorolac (Kc) idiosyncrasy. *Allergy* 1993; 48 Suppl. 16: 144
280. Fournier DC, Linehan AT, Hilman BC. A case of ketorolac induced asthma in an adult with aspirin sensitivity. *J Allergy Clin Immunol* 1991 Jan; 87: 275
281. Gijsbers AJ, Clarke BG. Ketorolac. *Med J Aust* 1993 May 17; 158: 720
282. Zikowski D, Hord AH, Haddox JD. Ketorolac-induced bronchospasm. *Anesth Analg* 1993 Feb; 76: 417-9
283. Haddow GR, Riley E, Isaacs R, et al. Ketorolac, nasal polyposis, and bronchial asthma: a cause for concern. *Anesth Analg* 1993 Feb; 76: 420-2
284. Hebert WG, Scopelitis E. Ketorolac-precipitated asthma. *South Med J* 1994 Feb; 87: 282-3
285. Goetz CM, Sterchele JA, Harchelroad FP. Anaphylactoid reaction following ketorolac tromethamine administration. *Ann Pharmacother* 1992 Oct; 26: 1237-8
286. Hare RM. Reaction to ketorolac. *Anaesth Intensive Care* 1993 Aug; 21: 477
287. Shapiro N. Acute angioedema after ketorolac ingestion: report of case. *J Oral Maxillofac Surg* 1994 Jun; 52: 626-7
288. Schaab KC, Dickinson ET, Setzen G. Acute sensorineural hearing loss following intravenous ketorolac administration. *J Emerg Med* 1995; 13 (4): 509-13
289. British National Formulary Number 31 ed. British Medical Society and Royal Pharmaceutical Society of Great Britain, London; 1996
290. Acute pain management in adults: operative procedures. *Am Fam Physician* 1992 July; 46 (1): 128-38
291. Acute pain management in infants, children and adolescents: operative and medical procedures. *Am Fam Physician* 1992 August; 46: 469-79
292. White PF. Management of postoperative pain and emesis. *Can J Anaesth* 1995 Nov; 42: 1053-5
293. Postoperative pain relief and non-opioid analgesics [editorial]. *Lancet* 1991 Mar 2; 337: 524-6

Correspondence: Jane C. Gillis, Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.
E-mail: demail@adis.co.nz

Errata

Vol 52, No. 5, page 735: In section 2.1, column 2, the first sentence of the last paragraph should read: '... and the *calculated* incidence of myocardial infarction ...'.

page 736: In figure 3, the order of parameters in the key should be: Total cholesterol, LDL cholesterol, HDL cholesterol, Triglycerides.

page 744: In section 4, column 2, line 6 should read: 'Animal data obtained using dosages much higher than those recommended ...'.

[Goa KL, Barradell LB, Plosker GL. Bezafibrate: an update of its pharmacology and use in the management of dyslipidaemia. *Drugs* 1996; 52 (5): 725-53]